Fintel on MSN1d
Leerink Partners Initiates Coverage of Camp4 Therapeutics (CAMP) with Outperform Recommendation
Fintel reports that on November 5, 2024, Leerink Partners initiated coverage of Camp4 Therapeutics (NasdaqGM:CAMP) with a ...
Fintel on MSN1d
William Blair Initiates Coverage of Camp4 Therapeutics (CAMP) with Outperform Recommendation
Fintel reports that on November 5, 2024, William Blair initiated coverage of Camp4 Therapeutics (NasdaqGM:CAMP) with a ...
CAMP4 Analyst Highlights Rare Disease Platform Potential
CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts ...
Camp4 gains after earning bullish views on Street
Camp4 Therapeutics (CAMP) stock gains after J.P. Morgan and Piper Sandler launched its coverage with Overweight ...
Camp4 Therapeutics initiated with an Overweight at Piper Sandler
Piper Sandler initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $18 price target The company is is pioneering ...
Camp4 Therapeutics initiated with an Outperform at Leerink
Leerink initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $17 price target The firm believes CMP-CPS-001, the lead ...